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Abstract
Background: Rett syndrome (RTT, MIM #312750) is a severe neurological disorder caused by mutations in the X-
linked methyl-CpG binding protein 2 (MECP2) gene. Female patients are affected with an incidence of 1/15000 live
births and develop normally from birth to 6-18 months of age before the onset of deficits in autonomic, cognitive,
motor functions (stereotypic hand movements, impaired locomotion) and autistic features. Studies on Mecp2
mouse models, and specifically null mice, revealed morphological and functional alterations of neurons. Several
functions that are regulated by bioaminergic nuclei or peripheral ganglia are impaired in the absence of Mecp2.
Results: Using high performance liquid chromatography, combined with electrochemical detection (HPLC/EC) we
found that Mecp2-/y mice exhibit an alteration of DA metabolism in the ponto-bulbar region at 5 weeks followed
by a more global alteration of monoamines when the disease progresses (8 weeks). Hypothalamic measurements
suggest biphasic disturbances of norepinephrine and serotonin at pathology onset (5 weeks) that were found
stabilized later on (8 weeks). Interestingly, the postnatal nigrostriatal dopaminergic deficit identified previously does
not parallel the reduction of the other neurotransmitters investigated. Finally, dosage in cortical samples do not
suggest modification in the monoaminergic content respectively at 5 and 8 weeks of age.
Conclusions: We have identified that the level of catecholamines and serotonin is differentially affected in Mecp2-/y
brain areas in a time-dependent fashion.
Background
Rett syndrome (RTT, MIM #312750) is a severe neurolo-
gical disorder caused by mutations in the X-linked
methyl-CpG binding protein 2 (MECP2) gene [1]. Female
patients are affected with an incidence of 1/15000 live
births [2,3] and develop normally from birth to 6-18
months of age before the onset of deficits in autonomic,
cognitive, motor functions and autistic features [4,5]. Sev-
eral studies shed light on the involvement of catechola-
minergic and serotonergic disturbances as a major
contributor of the disease in RTT patients and Mecp2
mouse models. Neurochemical analyses of biogenic
amines in Mecp2-null male (Mecp2-/y) were previously
performed on whole brain homogenates showing that the
concentration of dopamine (DA), norepinephrine (NE)
and serotonin (5-HT) was reduced after birth [6,7].
Moreover, the absence of Mecp2 impairs several func-
tions that are regulated by bioaminergic nuclei or periph-
eral ganglia where such neurochemical deficits occur
[8-12]. However, these studies are discordant for several
parameters. Here, we evaluated the level of DA, NE and
5-HT and their catabolites homovanillic Acid (HVA),
dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyin-
doleacetic acid (5-HIAA), using high performance liquid
chromatography, combined with electrochemical detec-
tion (HPLC/EC). We performed our analyses on micro-
punched brain samples from the cortex, caudate-
putamen, hypothalamus, midbrain (Substantia Nigra +
Ventral Tegmental Area) and the hindbrain (Brainstem +
Pons) (Figure 1) of Mecp2-/y mice and their respective
age-matched wild-type (WT) littermates from postnatal
day 35 (P35, disease onset) and 55 (P55, severe
phenotype).
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Figure 1 Summary of sampled sites. Cortical, Striatal (Caudate-Putamen), Hypothalamic, and Midbrain (Substantia Nigra + Ventral Tegmental
Area) micropunched sites (respectively at +1.18, 0.98, -0.82, -3.08 from Bregma) and Brainstem + Pons area sampled mapped onto plates
adapted from The Mouse Brain in Stereotaxic Coordinates atlas [39]. The pink circles/area mark sites were brain tissue was dissected out. Scale
bars, 1 mm.
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Results
Neither catecholamines nor serotonin levels are affected
in the cortex of Mecp2-/y
Neurochemical analysis performed in the cortex showed
no perturbation at P35 for DA, NE and 5-HT levels in
Mecp2-/y compared to their WT littermates (p > 0.05).
No significant alterations were observed at P55 for DA,
NE and 5-HT (p > 0.05). DA measurements in the cor-
tex display great variability possibly masking differences
between the two genotypes (Figure 2A). Dopaminergic
catabolites HVA and DOPAC were unaffected at P35
and P55 (p > 0.05). The serotonin metabolite 5-HIAA is
not different between Mecp2-/y and WT at P35 and P55
(p > 0.05) (Figure 3A). Altogether, these results argue
for a preserved biogenic amines metabolism in the cor-
tex of Mecp2-null mice.
The alteration of norepinephrine and serotonin levels in
the hypothalamus of Mecp2-/y is postnatal and biphasic
Next, we measured biogenic amines concentrations in the
hypothalamus. It was previously reported that a targeted
deletion of Mecp2 in Single-minded 1 gene (Sim1)-expres-
sing neurons (located in several hypothalamic nuclei)
results in a body of behavioural deficits ranging from feed-
ing disturbances to stress [13]. Increased levels of corticos-
terone and leptin together with Brain-derived neurotrophic
factor (Bdnf) deficits are possible contributors for this phe-
notype in this mouse. Since catecholamines play a role in
hypothalamic nuclei neurotransmission and interplays with
leptin and Bdnf [14-17] we wanted to assess deficits in bioa-
mines and their degradation products. Deficits were
observed at P35 for NE and 5-HT (p < 0.05). No alteration
of DA levels was noticed at this age (p > 0.05). However,
the NE and 5-HT decrease identified at P35 was no longer
present at P55 and DA levels were normal at P55 (p > 0.05)
(Figure 2B). All the tested catabolites were found to be nor-
mal in the hypothalamus of Mecp2-/y compared to WT at
P35 and P55 (Figure 3B).
Bioaminergic disturbances are global and progressive in
pontic and brainstem area of Mecp2-/y
DA, NE and 5-HT contents were evaluated by HPLC
using pons and brainstem samples of Mecp2-/y animals
and WT animals at P35 and P55 (Figure 2C). DA is
reduced both at P35 and at P55 (p < 0.05). NE levels are
normal at P35 (p > 0.05) but are clearly reduced at P55
(p < 0.05). For serotonin, we found the same pattern of
alteration, with no decrease at P35 (p > 0.05) but a
decrease at P55 (p < 0.05). Altogether, our results sug-
gest that Mecp2-/y mice have lower levels of biogenic
amines than their WT littermates.
We respectively assessed the level of HVA, DOPAC
and 5-HIAA in these samples (Figure 3C). At P35, the
only catabolite affected is HVA (p < 0.05) whereas
DOPAC and 5-HIAA are normal (p > 0.05). At P55, the
levels of HVA, DOPAC and 5-HIAA were all reduced in
Mecp2-/y compared to WT samples (p < 0.05).
Mecp2
-/y nigrostriatal dopaminergic deficits do not
parallel noradrenergic or serotonergic ones
We previously reported a postnatal reduction of DA and
HVA but not DOPAC in the caudate-putamen of
Mecp2-/y at P35 and P55 [12] (illustrated on Figure 2D
and Figure 3D). Here, we observed that at P35, neither
NE nor 5-HT contents were affected (p > 0.05). This
observation stands true for these neurotransmitters at
P55 (p > 0.05). We measured the level of 5-HIAA and
found no alteration at P35 (p > 0.05), and P55 (p > 0.05).
These results indicate that the noradrenergic and seroto-
nergic neurotransmitters are unaffected in the caudate-
putamen of Mecp2-/y compared to their WT littermates
at all ages investigated (Figure 2D and Figure 3D).
Our previous work failed to detect changes in the level
of DA and DOPAC in the Mecp2-/y midbrain at both
P35 and P55. However, we observed a clear reduction of
HVA in these dopaminergic neurons at the most
advanced age [12] (illustrated on Figure 2E and Figure
3E). We extended our analysis to NE, 5HT and 5-HIAA
at both ages. Our results show that NE is not altered at
P35 in Mecp2-deficient midbrain (p > 0.05). 5-HT levels
are also preserved compared to WT level at the same
age (p > 0.05). Samples obtained from symptomatic
mice (P55) do no exhibit any modification of the sub-
strate levels compared to age-matched WT (p > 0.05)
(Figure 2E). 5-HIAA values are normal at P35 (p > 0.05)
and at P55 (p > 0.05) in Mecp2-/y samples compared to
age-matched WT (Figure 3E).
Discussion
Mecp2-/y cortical neurons exhibit several alterations,
ranging from reduced activity to abnormal dendritic
spine morphology [18,19]. These defects are influenced
by Bdnf dosage [20]. Bdnf plays a key role in neuronal
survival, differentiation and synaptic plasticity [21]. Bdnf
metabolism was shown to be involved in the develop-
ment and function of catecholaminergic neurons,
affected in Mecp2-/y [22-25]. Recently, several studies
identified NE reductions in the piriform cortex of
Mecp2-null mouse at P35 [9] and in the prefrontal and
motor cortex at both 3 (P21) and 8 (P56) weeks of age
[11]. We were not able to reproduce these findings. One
possible explanation for this divergence could be differ-
ences in the sampling procedure. We performed micro-
punches of the motor cortex. Different cortical
territories receive monoaminergic inputs from different
nuclei, some areas being less densely innervated than
others [26]. Serotonergic dosage in Mecp2-/y brains were
also reported and discrepancies are existing. Isoda and
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Figure 2 Neurochemical analysis of catecholaminergic and serotonergic substrates. Measure of norepinephrine, serotonin and dopamine
content in the cortex (A, Cx), hypothalamus (B, Hyp), brainstem and pons (C, BP), caudate-putamen (D, CPu) and midbrain (E, Md) of Mecp2-/y
(white bars) and their WT littermates (black bars) at P35 (n = 6 Mecp2-/y, n = 10 WT for Cx, Hyp, BP and CPu - n = 6 Mecp2-/y, n = 9 WT for Md)
and P55 (n = 9 Mecp2-/y, n = 8 WT for Cx, Hyp, BP, CPu and Md). Results are expressed as mean +/- S.E.M., (*p < 0.05, **p < 0.01).
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Figure 3 Neurochemical analysis of dopaminergic and serotonergic catabolites. Measure of homovanillic acid (HVA), dihydroxyphenylacetic
acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) content in the cortex (A, Cx), hypothalamus (B, Hyp), brainstem and pons (C, BP), caudate-
putamen (D, CPu) and midbrain (E, Md) of Mecp2-/y (white bars) and their WT littermates (black bars) at P35 (n = 6 Mecp2-/y, n = 10 WT for Cx,
Hyp, BP and CPu - n = 6 Mecp2-/y, n = 9 WT for Md) and P55 (n = 9 Mecp2-/y, n = 8 WT for Cx, Hyp, BP, CPu and Md). Results are expressed as
mean +/- S.E.M., (*p < 0.05, **p < 0.01).
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collaborators did not to identify any modifications of 5-
HT and its main catabolite 5-HIAA in the prefrontal
cortex from P14 to P56 [10]. However, another labora-
tory argued for a reduction in the same structure of 5-
HT only, at 3 and 8 weeks of age [11]. As Isoda and
coauthors measured, we did not found significant reduc-
tions of 5-HT or 5-HIAA. Another group reported a 5-
HT deficit in whole brain extracts in the same develop-
mental window [7]. Unfortunately, samples used in this
study came from pooled 6 to 8 weeks Mecp2-/y animals,
two ages that are know to be phenotypically different
according to the postnatal development of the Mecp2-/y
mouse pathology [27]. These results thus combine 5-HT
contents from both mildly and severely affected animals.
It is generally believed that catecholamines play a role
in hypothalamic nuclei neurotransmission and that their
release is modulated by several factors including Bdnf
and leptin [17]. Here, we report a postnatal alteration of
hypothalamic NE and 5-HT contents that follows a
biphasic scheme. These biogenic amines were found sig-
nificantly decreased at P35 in Mecp2-/y animals whereas
their levels are not significantly different from WT at
P55. A recent study showed that specific deletion of
Mecp2 in Sim1-positive neurons in the paraventricular
nucleus (PVN) of the hypothalamus results in higher
serum level of leptin [13]. Since leptin was proposed to
lower NE-dependant oxytocin release in the PVN [17]
and to reduce firing of serotonergic neurons [28] it was
tempting to assess the level of bioamines in this brain
area. Our results at P35 could reflect a leptin-dependant
bioaminergic reduction. However, Fyffe and coauthors
did not identify alterations at 6 weeks (P42) but noticed
a significant increase 42 weeks. It is important to stress
that Mecp2-deletion is not restricted to hypothalamic
neurons in the model we used. Moreover, mice used in
one study were of mixed 129/FVB genetic background
[13] while we used C57Bl6 Mecp2-/y mice [29].
In agreement with Taneja and co-workers [9], we
found a reduction of DA and HVA in our hindbrain
samples containing both the brainstem and the pons at
P35. However, we did not found DOPAC reduction.
Taneja et al. used a different Mecp2-/y strain (i.e. gener-
ated by Jaenisch laboratory; [30]). It would be interesting
to investigate possible difference in the activity/modula-
tion of DA degradation enzymes in these two models.
In the Bird mouse [29] no difference was found in
monoamine oxydase (MAO-A and MAO-B) activity in
the cortex [11]. It remains to be determined if MAO
and/or catechol-O-methyl transferase (COMT) levels
are impaired elsewhere. Interestingly, the caudal struc-
tures are the most affected with dopaminergic distur-
bances at P35 when the Mecp2 animals display a mild
phenotype, and a global monoaminergic deficit at P55
affecting DA, NE, 5-HT and their degradation products.
This is in good agreement with several studies arguing
for a brainstem and pontic basis for the Mecp2-/y phe-
notype and RTT symptoms in humans [31,32]. The
observed increase in the serotonergic ratio (Table 1) at
P55 in the pons and brainstem supports a possible
alteration of 5-HT projections innervating this structure
and modulating the autonomic functions altered in the
absence of Mecp2 [33].
Mecp2-/y mice display a progressive and postnatal
alteration in their motor behavior [11,34]. Interestingly,
mice with a targeted deletion of Mecp2 in Th-expressing
neurons show a deficit in motricity among other dysre-
gulations [7]. We recently described in mice harboring a
constitutive deletion of Mecp2 progressive alterations of
Table 1 Metabolite/5-HT and metabolite/DA ratios in the
cortex, hypothalamus, caudate-putamen, midbrain and
brainstem/pons of WT and Mecp2-/y




Cortex P35 Wt 1.68 (+/- 0.14) 1.71 (+/- 0.42)
P35 Ko 1.88 (+/- 0.29) 1.33 (+/- 0.43)
P55 Wt 1.50 (+/- 0.17) 0.75 (+/- 0.10)
P55 Ko 1.47 (+/- 0.29) 0.77 (+/- 0.12)
Hypothalamus P35 Wt 1.92 (+/- 0.26) 0.85 (+/- 0.06)
P35 Ko 2.61 (+/- 0.37)
*
0.94 (+/- 0.12)
P55 Wt 1.37 (+/- 0.12) 0.73 (+/- 0.15)
P55 Ko 1.54 (+/- 0.22) 0.62 (+/- 0.09)
CaudatePutamen P35 Wt 1.91 (+/- 0.11) 0.47 (+/- 0.03)
P35 Ko 2.64 (+/- 0.22)
**
0.62 (+/- 0.05)
P55 Wt 1.06 (+/- 0.13) 0.30 (+/- 0.02)
P55 Ko 1.02 (+/- 0.08) 0.33 (+/- 0.02)
Midbrain P35 Wt 1.51 (+/- 0.23) 1.66 (+/- 0.14)
P35 Ko 1.79 (+/- 0.27) 1.64 (+/- 0.09)
P55 Wt 1.06 (+/- 0.13) 1.07 (+/- 0.13)
P55 Ko 1.02 (+/- 0.08) 0.99 (+/- 0.04)
Brainstem +
Pons
P35 Wt 2.27 (+/- 0.39) 0.36 (+/- 0.03)
P35 Ko 2.18 (+/- 0.31) 0.43 (+/- 0.09)
P55 Wt 1.17 (+/- 0.06) 0.44 (+/- 0.06)
P55 Ko 2.00 (+/- 0.51)
*
0.39 (+/- 0.02)
Shown are mean values +/- S.E.M. for the ratios of dopaminergic metabolites
HVA + DOPAC/DA and serotonergic metabolite 5-HIAA/5-HT in the cortex (Cx),
the hypothalamus (Hyp), the caudate-putamen (CPu), midbrain (Md) and
brainstem + pons (BP) of Mecp2-/y and their WT littermates at P35 and P55.
Dopamine turnover was unafected in the Cx, Hyp, CPu, Md and BP at both
P35 and P55 in Mecp2-/y compared to their age-matched WT littermates.
Serotonergic turnover was not modified in Cx and Md at any age
investigated. However, Hyp and CPu dosage revealed a significant increase of
5-HIAA/5-HT ratio at P35 but not P55. In turn, values from the BP indicate a
clear increase in the serotonergic turnover in Mecp2-/y when they exhibit the
most severe phenotype (P55). (*p < 0.05, **p < 0.01).
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the SNpc and the nigrostriatal dopaminergic pathway, a
key component of the brain motor circuitry [12]. More-
over, some of the behaviors impaired were ameliorated
by L-Dopa, arguing for a strong, although clearly non-
unique, involvement of the DA disturbances in Mecp2-/y
motor phenotype. In complement to this previous study,
we here pursued our neurochemical investigations for
NE and 5-HT in the SNpc and its striatal target. NE,
provided from the Locus Coeruleus, A1 and A2 (from
brainstem) is implicated in several brain functions and
its action on midbrain DA neurons was shown to mod-
ulate motivational behaviors [35,36]. The absence of NE
and 5-HT disturbances in the midbrain and the cau-
date-putamen confirm previous findings [10,11].
The consequence of Mecp2-deficiency on the integrity
of dopaminergic and serotonergic nuclei could be
indexed on the HVA + DOPAC/DA and 5-HIAA/5-HT
ratios respectively since a toxic alteration of dopaminer-
gic and serotonergic systems induces counteradaptative
processes that impact on this values [37,38]. The calcu-
lated ratios are reported in Table 1. Results suggest dopa-
mine turnover was left unaffected in all the structures
investigated at both P35 and P55 in Mecp2-/y compared
to their WT littermates. Conversely, hypothalamus and
caudate-putamen dosage revealed a significant increase
of 5-HIAA/5-HT ratio at P35 but not P55. Values from
the pons and brainstem indicate a clear increase in the
serotonergic turnover in Mecp2-/y at P55. However, this
index was not modified in the cortex and the midbrain at
P35 and P55. Alteration of the serotonergic innervation
lead to an increase in the turnover [37]. Interestingly, a
reduction in 5-HT immunoreactive fibers was reported
in the hippocampus of Mecp2-/y animals [10]. It remains
to be elucidated if such phenomenon contribute to sero-
tonergic deficits described here.
Conclusions
Our results indicate that the level of catecholamines and
serotonin is differentially affected in Mecp2-/y brain
areas in a time-dependent fashion (Figure 4). Consider-
ing behavioral and physiological function altered in the
context of Mecp2-deficiency and the positive impact of
drugs targeting this system, monoamine neurochemical
dosage could help identifying therapeutics resetting cen-




Experiments were performed on the B6.129P2(c)-
Mecp2tm1-1Bird mouse model for RTT [29]. The mice
were obtained from the Jackson Laboratories and main-
tained on a C57Bl/6 background. The experimental pro-
cedures were carried out in keeping with the European
guidelines for the care and use of laboratory animals
(Council Directive 86/609/EEC). Both pre-symptomatic
and symptomatic mice were analyzed at different devel-
opmental stages. A total number of 15 Mecp2-/y and 18
WT male mice were used in the study. The Mecp2 -/y
(null male) and WT (wild-type male) mice were studied
at postnatal days 35 (P35; n = 10 WT; n = 6 Mecp2-/y)
and 55 (P55; n = 8 WT; n = 9 Mecp2-/y) for neurochem-
ical analysis. Mecp2-deficient mice were compared to
their respective WT littermates of the same gender.
Breeding and genotyping were performed as previously
described [23].
Tissue sampling
P35 (n = 10 WT; n = 6 Mecp2-/y) and P55 (n = 8 WT; n
= 9 Mecp2-/y) mice were killed by cervical dislocation,
and their brains were dissected out within the first 2
min post-mortem. The motor cortex, Caudate-Putamen,
Midbrain area (Substantia Nigra + Ventral Tegmental
Area) were microdissected using a punching needle (0.5
mm ∅) and kept at -80°C until biochemical analysis.
The region containing both the Pons and the Brainstem
was dissected under a binocular microscope (Figure 1).
Briefly, brain area dissection was performed on cryostat
brain sections with the help of a 5× magnifying lens, fol-
lowing their stereotaxic coordinates [39,40].
Chemicals
Norepinephrine, DHBA, dopamine, DOPAC, HVA, ser-
otonin (5-hydroxytryptamine, 5-HT), 5-hydroxyindole-3-
acetic acid (5-HIAA), 1-octanesulfonic acid (OSA),
triethylamine and ethylene-diamine-tetra-acetic acid
(EDTA) disodium salt were purchased from Sigma,
sodium dihydrogen phosphate and citric acid from
Merck and methanol from Prolabo. Ultrapure water was
obtained with a Milli-Q system (Millipore, Bedford, MA,
USA). Standard solutions of each monoamine or meta-
bolite were stored at -20°C at 1 mmol/L as aliquots.
HPLC
The HPLC system was composed of a Hitachi L-7000
series equipped with a degasser, a L-7100 pump, an L-
7200 autosampler thermostated at 10°C and a Decade
Intro electrochemical detector fitted with a 3 mm glass
carbon working electrode, an Ag/AgCl reference elec-
trode and a 25 μm spacer (Antec, Leyden, The Nether-
lands). Separations were performed using a 250 mm ×
4.6 mm i.d. C18 5 μm Beckman Ultrasphere column
equipped with two Phenomenex C18 filters in a security
guard system. The mobile phase was pumped at a
microflow rate of 0.8 mL/min and composed of 0.7
mol/L sodium phosphate, 0.1 mmol/L EDTA, 1.1 mmol/
L OSA, 3.1 mmol/L triethylamine, 14% methanol, pH
adjusted to 3.12 with 1 mmol/L citric acid, it was
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filtered with 0.45 μm cellulose acetate membranes
before use. Elutes were detected at an oxidation poten-
tial of 700 mV versus reference electrode. The column
and the detection cell were housed within the Faraday
cage of the electrochemical detector that was set to
25.5°C. The day of the analysis, 35 μL samples were
placed in the autosampler and kept at +10°C before
injection. The injection volume was 30 μL. The reten-
tion times were 7 min, 11 min, 13.5 min, 16.5 min, 21
min, 32 min and 42 min for NE, DHBA, DOPAC, DA,
5-HIAA, HVA, and 5-HT, respectively.
Statistical analysis
We evaluated whether our data distribution fitted with a
Gaussian representation using a K-S Kolmogorov-Smir-
nov Normality test. If valid, data were statistically ana-
lyzed using unpaired Student’s t test. If not valid, we
used an adapted non-parametric Mann-Whitney test to
compare genotypes. The results are reported as mean
+/- standard error of the mean (S.E.M). A p-value <
0.05 was considered to be statistically significant.
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Figure 4 Summary of catecholaminergic & serotonergic neurochemical measurements in the Mecp2-/y brain. In mouse, Mecp2
dysfunction leads to the gradual postnatal reduction of dopamine (DA), norepinephrine (NE), serotonin (5-HT) and their principal degradation
product dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 5-hydroxyindolacetic acid (5-HIAA) in several neuronal populations.
These monoaminergic nuclei-related perturbation result in characterized phenotypes that constitute some of the key features of RTT pathology
in humans. Sagittal mouse brain drawing adapted from The Mouse Brain in Stereotaxic Coordinates atlas [39]. Area fill in green depict the cortical
mantle. In gray the substantia nigra pars compacta (SNpc) irradiating the caudate-putamen (CPu) through the medial forebrain bundle (mfb).
Hypothalamic (Hyp) region is symbolized in purple and the pons + brainstem in pink. OB (olfactory bulb), c.c (corpus callosum), CB (cerebellum),
LV (lateral ventricle), IV (4th ventricle). Scale bar, 1 mm.
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